Objective: To explore the clinical effect of combining fractional laser with fibroblast growth factor in the treatment of facial depressive scars. Methods: Fifty patients with facial depressive scars admitted to our hospital from February to November 2025 were selected as the research subjects. They were randomly divided into the control group and the study group, with 25 cases in each group. The control group received only fractional laser treatment, while the study group received fractional laser combined with fibroblast growth factor treatment. The Vancouver Scar Scale (VSS), treatment effectiveness, improvement of skin flatness, and patient satisfaction were compared between the two groups before and after treatment. Results: The VSS scores of the study group at 1, 2, 3, 4, and 6 weeks after intervention were all lower than those of the control group (P < 0.05); the treatment effectiveness of the study group (96.00%) was higher than that of the control group (60.00%) (P < 0.05); the skin flatness of the study group improved compared with the control group after intervention (P < 0.05); the satisfaction rate of the study group (100.00%) was higher than that of the control group (72.00%) (P < 0.05). Conclusion: Combining fractional laser with fibroblast growth factor in the treatment of facial depressive scars can significantly improve the treatment effectiveness of patients, reduce the degree of scar depression, and is an effective clinical treatment plan, which is worthy of clinical application.